Acute graft versus host disease

7 trials 1 recruiting MedDRA PT
7 Registered trials
1 Recruiting
5 Unique sponsors
7 Unique IMPs
7 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
HDAC inhibitor 1 substance
Kinase inhibitor 1 substance
Phase III: 1 Phase II: 4 Phase IV: 1 Phase I (First in Human): 1

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase III

1 trial
  • Medac Gesellschaft fuer klinische Spezialprapaerate mbH Commercial
    MESENCHYMAL STROMAL CELLS, EX VIVO CULTURED
    2023-505737-26-00 4 countries 2020 n=210 Orphan
    Recruiting

Phase II

4 trials
  • Cynata Therapeutics Limited Commercial
    ALLOGENEIC MESENCHYMOANGIOBLAST-DERIVED MESENCHYMAL STEM CELLS
    2022-502673-41-01 4 countries 2024 n=38
    Ended
  • Medac Gesellschaft fuer klinische Spezialprapaerate mbH Commercial
    MESENCHYMAL STROMAL CELLS, EX VIVO CULTURED
    2023-503952-28-00 5 countries 2023 n=54 Orphan
    Ended
  • Realta Life Sciences Inc. Commercial
    ILE-ALA-LEU-ILE-LEU-GLU-PRO-ILE-CYS-CYS-GLN-GLU-ARG-ALA-ALA-(DISCRETE-POLYETHYLENE GLYCOL)24
    2024-510582-42-00 2 countries n=16 Orphan
    Not authorised
  • Realta Life Sciences Inc. Commercial
    ILE-ALA-LEU-ILE-LEU-GLU-PRO-ILE-CYS-CYS-GLN-GLU-ARG-ALA-ALA-(DISCRETE-POLYETHYLENE GLYCOL)24
    2024-510582-42-02 2 countries 2025 n=16 Orphan
    Ended

Phase IV

1 trial
  • Novartis Pharma Services AG Commercial
    PANOBINOSTAT; RUXOLITINIB; SIREMADLIN
    2024-515283-31-00 4 countries 2015 n=33 Orphan
    Ended

Phase I (First in Human)

1 trial
  • ActiTrexx GmbH Commercial
    ALLOGENEIC CD4+ AND CD25+ T LYMPHOCYTES EX VIVO INCUBATED WITH GP120
    2024-516599-14-00 1 country 2023 n=10 Orphan
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Medac Gesellschaft fuer klinische Spezialprapaerate mbH Commercial 2 Phase II, Phase III 1
Realta Life Sciences Inc. Commercial 2 Phase II 0
Cynata Therapeutics Limited Commercial 1 Phase II 0
Novartis Pharma Services AG Commercial 1 Phase IV 0
ActiTrexx GmbH Commercial 1 Phase I (First in Human) 0
New trials by year
2020
1
2023
2
2024
1
2025
1
← All indication landscapes